AbbVie (NYSE:ABBV) Releases Q4 2025 Earnings Guidance

AbbVie (NYSE:ABBV) updated its fourth quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 3.320-3.360 for the period, compared to the consensus earnings per share estimate of 3.360. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 10.610-10.650 EPS.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ABBV shares. Scotiabank began coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. BMO Capital Markets boosted their price target on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Finally, Raymond James Financial set a $256.00 target price on shares of AbbVie in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $246.89.

AbbVie Stock Performance

ABBV opened at $233.65 on Thursday. The business has a 50 day moving average price of $226.63 and a 200 day moving average price of $214.80. AbbVie has a twelve month low of $164.39 and a twelve month high of $244.81. The firm has a market cap of $412.95 billion, a P/E ratio of 177.01, a price-to-earnings-growth ratio of 0.94 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter last year, the company posted $3.00 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts anticipate that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Berenberg Bank raised AbbVie to a Buy, providing an analyst-driven demand tailwind that can support near-term share gains. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Multiple reports (WSJ/Reuters) said AbbVie was in advanced talks to acquire Revolution Medicines, fueling takeover speculation that typically lifts a buyer’s stock ahead of any deal announcement. AbbVie Near Deal for Revolution Medicines AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
• Positive Sentiment: AbbVie expanded its oncology pipeline with a first‑in‑human ABBV‑901 trial in ovarian cancer — a pipeline development that supports longer‑term growth narratives beyond legacy assets. AbbVie Expands Ovarian Cancer Pipeline With New ABBV‑901 Trial
• Neutral Sentiment: Revolution Medicines shares jumped on the takeover rumors (market context), which contributed to intraday volatility in AbbVie-related news flow but doesn’t change AbbVie’s fundamentals unless a deal is announced. Revolution Medicines stock surges over 20%
• Neutral Sentiment: AbbVie scheduled its full‑year and fourth‑quarter 2025 earnings release and conference call for Feb. 4 — a routine event that will be the next formal opportunity for management to set expectations and move the stock. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Neutral Sentiment: UBS reiterated a Hold rating, highlighting a balanced risk/reward given AbbVie’s premium valuation versus long-duration growth — a reminder that some analysts see limited upside from here. AbbVie: Premium Valuation… Hold Rating
• Negative Sentiment: AbbVie updated guidance: Q4 2025 EPS 3.320–3.360 and FY2025 EPS 10.610–10.650, each nudging slightly under consensus — a conservative tilt that can cap upside and explain some profit‑taking. (Company guidance released 1/8/2026)
• Negative Sentiment: After takeover reports, AbbVie publicly denied talks to buy Revolution Medicines, which may roll back some of the acquisition-driven rally and increase short-term volatility. Abbvie denies WSJ report of talks to buy Revolution Medicines
• Negative Sentiment: Competitive pressure: J&J’s Tremfya outspent AbbVie’s Skyrizi on TV ads through December, underscoring intense competition in immunology that can pressure market share and pricing over time. Tremfya outstrips Skyrizi in TV ad spend

Institutional Investors Weigh In On AbbVie

Hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC grew its holdings in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. Schnieders Capital Management LLC. boosted its position in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares in the last quarter. Ieq Capital LLC lifted its stake in AbbVie by 4.6% during the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after purchasing an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC boosted its holdings in AbbVie by 117.3% during the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after purchasing an additional 612,702 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.